By admin 
The Rudensky Symposium on Immunity, Inflammation and Tolerance, held from August 27 to 28, 2026, transcended the typical boundaries of a scientific conference. This two-day event served as a profound celebration of Dr. Alexander “Sasha” Rudensky’s 70th birthday, bringing together a distinguished assembly of former trainees, collaborators, and esteemed colleagues from across the globe. Dr. Rudensky, a revered immunologist at Memorial Sloan Kettering Cancer Center (MSKCC), has profoundly shaped the field of immunology, particularly through his seminal work on regulatory T cells (Tregs). The symposium was not merely a platform for scientific discourse but a heartfelt tribute to decades of intellectual partnership, shared scientific discovery, and the enduring mentorship that has shaped countless careers. Throughout the meticulously curated scientific presentations, personal anecdotes and shared memories were interwoven, painting a vivid picture of the deep professional and personal relationships fostered under Dr. Rudensky’s guidance.
The Cancer Research Institute (CRI) proudly served as a key supporter of this landmark symposium, celebrating a distinguished member of its Scientific Advisory Council (SAC). For over two decades, CRI has been a steadfast champion of Dr. Rudensky’s groundbreaking research and his exceptional commitment to nurturing the next generation of scientific leaders. This extensive support has included funding for more than a dozen CRI-sponsored fellows who have trained within his influential laboratory, many of whom have gone on to establish their own impactful research programs. Dr. Rudensky’s contributions to immunology were formally recognized in 2015 when he received the prestigious CRI William B. Coley Award for his pioneering work on regulatory T cells. These specialized immune cells are crucial for maintaining immune homeostasis, restraining excessive immune responses, and protecting healthy tissues from autoimmune damage—a fundamental concept with far-reaching implications for both autoimmune diseases and cancer.
CRI’s deep connections within this scientific community underscore its enduring commitment to funding both basic immunology and its application to cancer research. This foundational support is rooted in the conviction that a comprehensive understanding of the intricate mechanisms governing the immune system is indispensable for effectively harnessing its power to combat cancer. The symposium itself exemplified this philosophy, demonstrating how insights derived from fundamental biological questions, often not initially focused on cancer, frequently unveil principles critical to cancer prevention, development, metastasis, and therapeutic response.
A Legacy of Discovery: Dr. Alexander Rudensky’s Impact on Immunology
Dr. Alexander Rudensky’s journey to becoming one of the world’s foremost immunologists is marked by relentless curiosity and groundbreaking discoveries. Born in 1956, Dr. Rudensky emigrated from Russia, eventually establishing his formidable research career in the United States. His most significant contributions center on regulatory T cells, or Tregs. Before his work, the understanding of immune tolerance was incomplete. Rudensky’s lab was instrumental in identifying the transcription factor Foxp3 as the master regulator of Treg development and function. This discovery, detailed in landmark papers in the early 2000s, revolutionized the field, providing a molecular handle to study and manipulate these crucial cells. Tregs, a subset of T lymphocytes, are essential for preventing autoimmunity and limiting chronic inflammation, yet they also pose a challenge in cancer immunology by suppressing anti-tumor immune responses, allowing malignancies to evade detection and destruction.
His receipt of the CRI William B. Coley Award in 2015 highlighted the profound impact of his work on our understanding of immune regulation. The Coley Award, named after Dr. William B. Coley, a pioneer in cancer immunotherapy, recognizes scientists who have made seminal contributions to the field of tumor immunology. For Dr. Rudensky, this award acknowledged not just the discovery of Foxp3’s role but the broader implications for designing therapies that could either enhance Treg function in autoimmune diseases or suppress it in cancer to unleash anti-tumor immunity. The symposium, therefore, was not just a birthday celebration but a testament to a career defined by foundational discoveries that continue to drive new avenues of research and potential clinical interventions.
Basic Science Illuminates Tissue Homeostasis and Disease
A recurring theme throughout the symposium was the revelation that many biological processes governing healthy tissue balance also profoundly influence cancer initiation, progression, and response to treatment. Several presentations underscored how seemingly disparate biological questions could yield insights directly relevant to oncology.
Dr. Ruslan Medzhitov, a CRI scientist and 2003 CRI Coley Awardee, presented compelling research on how stressed cells recruit macrophages to clear damaged proteins, akin to an immune system "maintenance crew." This work suggests that immune cells possess broader functions beyond mere defense against pathogens, actively participating in tissue repair and maintaining cellular integrity. The implications for cancer are significant; a dysregulated cellular environment, prone to accumulating damaged components, could foster conditions conducive to tumor growth, making the immune system’s maintenance role a potential target for intervention.
Further expanding the understanding of Tregs beyond their immunosuppressive role, Dr. Diane Mathis, a 2024 CRI Coley Awardee, detailed populations of Tregs that actively participate in muscle repair. These specialized Tregs control inflammation, guide regenerative processes, and limit fibrotic scarring in injured tissues. Concurrently, Dr. Christophe Benoist, also a 2024 CRI Coley Awardee, demonstrated how the specific molecular targets recognized by Tregs could dictate their identity and functional specialization. These findings challenge the monolithic view of Tregs, revealing a nuanced landscape where their functions are finely tuned to specific tissue environments and immunological challenges. This precision in immune restraint is paramount: insufficient regulation can lead to debilitating autoimmunity and tissue destruction, while excessive suppression can create an permissive environment for cancer evasion and growth. Understanding these context-dependent roles is critical for developing therapies that selectively modulate Treg function without inducing widespread immune dysfunction.
The Immune System’s Early Warning System: Pre-Cancer Immunosurveillance
A particularly exciting frontier explored at the symposium was the concept of early cancer immunosurveillance, where the immune system may act even before a visible tumor manifests. Dr. Richard A. Flavell, a CRI scientist and 2012 CRI Coley Awardee, presented groundbreaking preclinical work investigating how the immune system might detect and eliminate mutant intestinal stem cells long before they form established tumors. In mouse models, cells harboring a BRAF mutation—a common oncogenic driver—gained a competitive survival advantage. However, many of these potentially dangerous cells were still eliminated, suggesting an active immune policing mechanism.
Dr. Flavell’s experiments indicated that immune recognition is a crucial determinant of which abnormal cells survive in the early stages of oncogenesis. When mutant cells lost a key molecule essential for communicating with T cells, they were more likely to proliferate and dominate the small compartments where intestinal stem cells reside. Intriguingly, Tregs and the immune cytokine IL-10 also appeared to play a role in restraining these nascent cancerous clones. This preclinical work offers a powerful conceptual framework: the immune system may actively influence cancer development from the earliest moments a potentially dangerous cell emerges and begins to compete with its healthy neighbors. This opens up entirely new avenues for cancer prevention strategies focused on bolstering this early immunosurveillance.
Complementing this, Dr. Julien C. Marie explored the intricate link between inflammation and cancer from a different perspective. His research in mice demonstrated that disrupting a critical regulatory signal, TGF-β, could push intestinal Th17 cells—another type of immune cell—into a state of persistent inflammation. This chronic inflammatory state was associated with localized DNA damage and, eventually, cancer development. Importantly, restoring the TGF-β signal reversed aspects of this harmful inflammatory program, suggesting that even established inflammatory pathways leading to cancer may retain a degree of plasticity and responsiveness to targeted interventions. These findings highlight the dynamic interplay between immune signaling, chronic inflammation, and cancer risk.
The Tumor Ecosystem: A Complex Interplay with Immunity
The symposium also delved into the complex tumor microenvironment, emphasizing that cancer progression and therapeutic response are deeply intertwined with the surrounding cellular ecosystem. Dr. Dan Littman, a CRI SAC member and 2016 CRI Coley Awardee, presented compelling preclinical research linking the gut microbiome to cancer immunotherapy outcomes. His work elucidated how gut bacteria "train" T cells and significantly influence responses to checkpoint immunotherapy, illustrating how immune responses originating in the intestine can exert systemic effects on cancer located in distant parts of the body. This research underscores the critical importance of the microbiome as a modulator of anti-tumor immunity, suggesting potential strategies to enhance therapeutic efficacy through gut microbial manipulation.
Dr. Paula D. Bos presented innovative research on how Tregs can influence breast cancer progression through their interactions with macrophages and the physical extracellular matrix (scaffolding) surrounding a tumor. Temporarily depleting Tregs in mouse models of breast cancer shifted macrophages towards a tumor-fighting (anti-tumorigenic) state and disrupted the aligned collagen fibers that can act as "highways" for cancer cell escape. Consequently, these mice exhibited fewer circulating tumor cells and a reduced burden of metastatic disease. This work highlights that the goal is not a broad elimination of Tregs, which could induce severe autoimmune side effects, but rather to uncover specific mechanisms to precisely influence macrophage behavior and impede tumor spread.
Further exploring the tumor’s ability to create immune-suppressive "neighborhoods," Dr. Nicholas Arpaia identified a specific fibroblast population that actively recruits suppressive Tregs around lung tumors. This discovery provides a potential target for therapies aimed at disrupting the immune-suppressive architecture of the tumor microenvironment. Dr. Arpaia also described collaborative work with CRI Lloyd J. Old STAR Tal Danino, PhD, leveraging engineered bacteria to deliver immunomodulatory therapies directly into tumors. This innovative approach aims to concentrate immune-activating treatments precisely where they are needed, minimizing systemic toxicity and maximizing therapeutic effect. These studies collectively emphasize the intricate cellular and molecular landscape within tumors and the potential for targeted interventions that disrupt immune evasion mechanisms.
Progress Forged Through People: Mentorship, Collaboration, and Enduring Legacy
Beyond the groundbreaking scientific presentations, the Rudensky Symposium served as a powerful reminder that advances in cancer research are profoundly rooted in fundamental questions about immune cells, tissue dynamics, and their complex interactions. Crucially, the symposium underscored that scientific progress is inextricably linked to mentorship, robust collaboration, intellectual rigor, and the invaluable freedom to pursue questions whose immediate clinical relevance may not always be apparent.
The palpable energy in the room, with generations of scientists gathered to celebrate their mentor, made the "ripple effect" of scientific training and collaboration vividly tangible. For over 70 years, the Cancer Research Institute has steadfastly invested in this foundational ecosystem of discovery, supporting not only the cutting-edge science but also the talented individuals who carry it forward. The Rudensky Symposium brought this long-term commitment to life: witnessing former trainees evolve into influential mentors themselves, observing how initial discoveries informed entirely new fields of inquiry, and experiencing the vibrant network of collaborations that connect fundamental biological questions to the ultimate shared goal of improving patients’ lives. Dr. Rudensky’s 70th birthday celebration was, in essence, a profound testament to the power of human connection in driving scientific breakthroughs and ensuring a lasting legacy of innovation.
